A bathroom scale with a tape measure and an apple

Obesity

Also called overweight, weight loss, BMI, clinical obesity, GLP-1, semaglutide, tirzepatide, Wegovy, Zepbound

Excess body fat that harms health. New medicines produce 15–20% weight loss and lower the risk of heart attack and stroke, and a 2025 definition looks beyond BMI.

Updated 5 sources

Photo: rawpixel (CC0)

This entry is a draft and is still being reviewed.

Types

  • A 2025 Lancet Commission separates clinical obesity — excess body fat that is already impairing organs or everyday activities — from preclinical obesity, excess fat with normal function but higher future risk1.
  • BMI categories for adults: 25–29.9 overweight and 30 or higher obesity, with lower cutoffs often used for people of Asian descent.
  • Monogenic obesity — rare, severe, early-onset obesity caused by a single gene.

Prevention

  • Prevention focuses on diet quality, regular activity, enough sleep, and surroundings that make healthy choices easier.

Risk factors

  • Genetics, including common variants such as FTO5
  • Calorie-dense, highly processed foods and sugary drinks
  • Physical inactivity and short sleep
  • Some medications, including certain antipsychotics, steroids, and insulin
  • Hormonal conditions such as hypothyroidism, polycystic ovary syndrome, and Cushing's syndrome

Diagnostics

  • BMI alone isn't enough. Confirm excess fat with waist circumference, waist-to-hip or waist-to-height ratio, or a direct body-fat measurement such as a DEXA scan1.
  • Look for effects on the body: blood pressure, blood sugar, cholesterol, liver tests, sleep apnea, and joint pain or limited mobility1.

Treatments

  • Lifestyle: diet, activity, and behavior change.
  • Medication: semaglutide 2.4 mg led to 14.9% average weight loss over 68 weeks, compared with 2.4% on placebo2. Tirzepatide led to up to 20.9% weight loss over 72 weeks3.
  • Heart protection: in people with cardiovascular disease and overweight or obesity but no diabetes, semaglutide cut heart attacks, strokes, and cardiovascular deaths by 20%4.
  • Metabolic and bariatric surgery produces the largest lasting weight loss.
  • Weight tends to return when medication stops, so treatment is usually long-term.

Molecular Biomarkers

  • No lab test diagnoses obesity. Labs look for its effects, including HbA1c, cholesterol, liver enzymes, and sometimes thyroid tests1.
  • Hormones such as leptin are measured only in research or suspected genetic cases.

Genes

  • A common variant in FTO was the first gene variant linked to body weight: people with two copies weigh about 3 kg more on average5.
  • Rare single-gene causes, in genes such as MC4R, LEPR, POMC, and PCSK1, cause severe obesity in childhood; some respond to the drug setmelanotide.

Lifestyle

  • Aim for 150 to 300 minutes a week of moderate activity, plus strength training to protect muscle while losing weight.
  • Sleep 7 to 9 hours a night.
  • Tracking food and weight and joining a support program improve results.

Nutrition

  • The best diet is one you can keep up; cutting calories matters more than the exact mix of carbs and fat.
  • Build meals around protein, vegetables, and fiber, and limit highly processed foods and sugary drinks.
  • On GLP-1 medicines, eat enough protein and drink enough fluids.

Medical Interventions

  • Metabolic and bariatric surgery: sleeve gastrectomy and gastric bypass
  • Endoscopic procedures: endoscopic sleeve gastroplasty and intragastric balloons

Pharmaceutical Drugs

  • Semaglutide — weekly injection; a daily pill version was approved by the FDA in December 20252,4
  • Tirzepatide — weekly injection3
  • Liraglutide — daily injection
  • Phentermine-topiramate, naltrexone-bupropion, and orlistat
  • Setmelanotide for specific genetic causes
  • These medicines aren't used during pregnancy; their most common side effects are nausea and other digestive symptoms2,3.

Sources

  1. Rubino F, Cummings DE, Eckel RH, et al. Definition and diagnostic criteria of clinical obesity. Lancet Diabetes Endocrinol. 2025;13(3):221-262. doi:10.1016/S2213-8587(24)00316-4
  2. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002. doi:10.1056/NEJMoa2032183
  3. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216. doi:10.1056/NEJMoa2206038
  4. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221-2232. doi:10.1056/NEJMoa2307563
  5. Frayling TM, Timpson NJ, Weedon MN, et al. A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity. Science. 2007;316(5826):889-894. doi:10.1126/science.1141634

This page summarizes published research for education. It isn't medical advice and doesn't replace care from a clinician who knows your history. Never start, stop, or change a medication without talking to your prescriber.